Amgen Inc.

Global Blood Therapeutics, Inc.

Lantheus Medical Imaging, Inc.

Cytokinetics, Inc.

Ming Yu

Zhe Li

Manuel Zancanella

Julio Cesar Medina

Simon P Robinson

David S Casebier

Liusheng Zhu

Zice Fu

Sean P Brown

Yingcai Wang

Marc Vimolratana

Jonathan B Houze

Qing Xu

Jiwen Liu

Ana Zurisadai Gonzalez Buenrostro

Zhihong Li

Mike Elias Lizarzaburu

Lina Quattrocchio Setti

Hing L Sham

Wang Shen

Heike S Radeke

Thomas David Harris

Ajay Purohit

Brian Stuart Lucas

Michael T Azure

XianYun Jiao

SuJen Lai

Christophe Beraud

Xiaohui Du

Roman Sakowicz

Xiaodong Wang

Xuelei Yan

Zhihua Ma

Michael G Johnson

Paul John Dransfield

Yosup Rew

Felix Gonzalez Lopez De Turiso

Vatee Pattaropong

Xianghong Wang

Jason A Duquette

Calvin Wesley Yee

Todd J Kohn

Yunxiao Li

Richard V Connors

Jeffrey Deignan

Julie Anne Heath

Richard R Cesati

Jiasheng Fu

Joshua Taygerly

Michael W Gribble, Jr

Jiang Zhu

Lawrence R McGee

Frank Kayser

Xiaoqi Chen

Daqing Sun

Jeffrey Thomas Mihalic

Dustin L McMinn

David John Kopecky

Leping Li

Jonathan Dante Low

Brian M Fox

Michael D Bartberger

John Eksterowicz

Hilary Plake Beck

Darin J Gustin

Steven H Olson

Joel McIntosh

Nick A Paras

Philip M Roveto

Brian Walter Metcalf

Yasuyuki Ogawa

Jian Luo

Xiaolin Hao

Alan C Cheng

Mario G Cardozo

Hui Tian

Kexue Li

Eugeni Vaisberg

David C Onthank

An-Rong Li

Sarah Lively

Gayathri Swaminath

Zhaodan Cao

Carol Hui Hu

Joel Lazewatsky

Xian Yun Jiao

Yihong Li

Xin Huang

Benjamin Fisher

Zhongyu Wang

Satoshi Shibuya

Jie Zhang

Narihiro Toda

Michael R Degraffenreid

YuMei Xiong

Jinqian Liu

Yongli Su

Matthias Broekema

A method of imaging, the method comprising administering, to a subject, a compound of Structure Alpha, of the formula:

Ligands for imaging cardiac innervation

The present disclosure provides compounds of Formula (I) that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds. where R, alk, R, Z, Z, X, R, R, B, a, and b are as described herein.

Histone methyltransferase inhibitors

The present disclosure provides certain tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Tricyclic compounds as histone methyltransferase inhibitors

The present disclosure provides tricyclic compounds of formula (I) that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds. 

The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I: and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.

Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Compounds that inhibit MCL-1 protein

The present disclosure provides certain compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinpathies such as beta-thalassemia and sickle cell disease. Also provided are pharmaceutical compositions containing such compounds as well as processes and intermediates for preparing such compounds.

Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release thereby reducing side effects, improved quantitative data, and/or high affinity for VMAT over prior radiotracers. In some instances the compounds are developed by derivatizing certain compounds with 18F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.

The present disclosure provides certain angular tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Azaindole compounds as histone methyltransferase inhibitors

The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.

Modulators of hemoglobin

The present disclosure provides compounds of Formula (I) that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinpathies (e.g., beta thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds. where R, alk, R, Z, Z, X, R, R, B, a, and b are as described herein.

The present invention is directed, in part, to compounds and methods for imaging the central nervous system or cancer, comprising administering to a subject a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the subject using diagnostic imaging.

Contrast agents for applications including perfusion imaging

Provided herein are kallikrein modulating compounds, pharmaceutical compositions comprising the same, and uses thereof.

Bridged bicyclic kallikrein inhibitors

Compounds that inhibit Mcl-1 protein

Growing community of inventors

Foster City, CA, United States of America

Ming Yu